Would you buy Avanex? Earnings for the week starting 23Dec24
Earnings Calendar (23Dec24)
Due to the holiday season, there are 2 notable earnings this week - Anavex and Limoneira.
Let us look at Anavex.
Who is Anavex?
Anavex has clocked a price decline of 3.6% from a year ago.
The EPS is -0.50 and thus, has a (negative) P/E ratio of -17.2
From the technical analysis, it has a “Neutral” rating.
From Analysts Sentiment, it has a recommendation for “Strong Buy”. Its price target of $35.472 implies an upside of 311.031%.
The company has yet to generate any revenue, making a loss from the last 10 years as per the screenshot above.
The operating losses peaked at $56M in 2023.
For the coming earnings, the forecast of its EPS and Revenue are -0.157 and no revenue respectively.
It seems that the company will end the last quarter with a loss. There are some products in clinical trials and the outlook of these would be important for the business.
I do not know this industry adequately and prefer to skip Avanex.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- TimothyBarnes·12-23Interesting analysis1Report